Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARX788 in HER2-mutated or HER2-amplified Solid Tumors
NCT05041972Phase 2Withdrawn
- Sponsor
- Ambrx
- Start
- Nov 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of anvatabart opadotin in solid tumor, non-small cell lung cancer (NSCLC), breast cancer, biliary tract cancer (BTC), colorectal cancer (CRC), sponsored by Ambrx. Planned start Nov 2021; status: withdrawn.
02
Drugs
anvatabart opadotin
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)breast cancerbiliary tract cancer (BTC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05041972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041972.